BRISTOL-MYERS SQUIBB COMPANY Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements of $120.00 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements · last filed 2014-02-14
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2013 was $120.00M, a 126.42% increase from fiscal 2012.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2012 was $53.00M, a 1.92% increase from fiscal 2011.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2011 was $52.00M, a 24.64% decline from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, settlements for fiscal 2010 was $69.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements 12 month |
|---|---|
| 2013-12-31 | $120.00M 10-K · filed 2014-02-14 |
| 2012-12-31 | $53.00M 10-K · filed 2014-02-14 |
| 2011-12-31 | $52.00M 10-K · filed 2013-02-15 |
| 2010-12-31 | $69.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |